Home | HIV Information | Indevus Pharmaceuticals Announces Completion Of Enrollment In Phase III Trial Of PRO 2000

Indevus Pharmaceuticals Announces Completion Of Enrollment In Phase III Trial Of PRO 2000

22 August, 2008 10:00:00 Medical News Today
Font size: Decrease font Enlarge font
Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced the completion of enrollment in Protocol MDP 301, a Phase III clinical trial of PRO 2000, the Company's candidate vaginal microbicide for the prevention of HIV and other sexually transmitted infections.

Comments (0 posted):

Post your comment comment

Please enter the code you see in the image:

  • email Email to a friend
  • print Print version
  • Plain text Plain text
Tags
No tags for this article
Rate this article
0
Powered by Vivvo CMS v4.0